



PATRIZIA GIANNATEMPO

EDUCATION

MD Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
University of Milan, Italy March 2022
Dissertation: "NEW TREATMENT TARGETS AND MECHANISMS OF RESISTANCE TO
ANTIANGIOGENIC DRUGS: A DEVELOPMENT STRATEGY IN UROTHELIAL NEOPLASMS."
Committee: M. Gianni (chair), A. Necchi

Medical degree University of Milan, Italy
September 2007
70/70
Title of the dissertation in Medicine and Surgery: "Wilms Tumor stage IV: retrospective study of
National Cancer Institute of Milan experience".

RESEARCH EXPERIENCE

Dissertation: Fondazione IRCCS Istituto Nazionale dei Tumori di Milan, Italy 2013
Advisor: prof. A. Necchi
Lab activities on the project "A pre-clinical study of the selective CDK4_6 Inhibition PD0332991
(Palbociclib) in association with a selective MEK inhibitor PD-0325901 in transitional cell carcinoma (TCC)
of the bladder."

Institution/Company/Organization,
Fondazione IRCCS Istituto Nazionale dei Tumori di Milan, Italy 2015-2016
Position Advisor: prof A. Necchi
Lab activities on the project "Next generation sequencing of teratoma with malignant transformation
(TMT) to uncover potentially meaningful insights into the biology of germ cell tumors"

Company/Organization, Fondazione IRCCS INT Milan, Italy 2020 to 2024
Position Principal investigator for the following accademic clinical studies:

INT 180/18: ARCADIA – no profit Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial
INT 42/18: PEANUT: Phase 2 study with the anti-PD-1 monoclonal antibody pembrolizumab, associated with nab-paclitaxel, in patients with locally advanced / metastatic urothelial neoplasms relapsed or refractory to the first line of chemotherapy treatment

ADDITIONAL EXPERIENCE/PROFESSIONAL DEVELOPMENT

Panel member of: Italian National Guidelines AIOM Urothelial Carcinoma 2021-2025
Panel member of: Italian National Guidelines AIOM Germ cell Tumor 2020-2025
Panel member of: ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up 2018
Panel member of: EORTC European Organization for Research and Treatment Treatment of Cancer – Genito-Urinary group from 2024
Panel member of: Workshop on Methods in Clinical Cancer Research (MCCR) from 2024

Name of University, University of Milan, Italy
As Faculty in a Master palliative therapy in medical oncology 2012 -2013

PUBLICATIONS

Books

Author of a chapter of the book: "Advances in the first and second line chemotherapy of Small Cell Lung Cancer" Demos series in oncology, Emerging Cancer Therapeutics [2]

Journal Publications

1. Ferrari A, Miceli R, Meazza C, Casanova M, Favini F, Morosi C, Trecate G, Marchianò A, Luksch R, Cefalo G, Terenziani M, Spreafico F, Polastri D, Podda M, Catania S, Schiavello E, **Giannatempo P**. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. *J Clin Oncol*. 2010 Mar 10;28(8):1322-8.
2. Advances in the first and second line chemotherapy of small cell lung cancer" -Demos series in oncology, Emerging Cancer Therapeutics, Dr. Jame Abraham as series editor
3. Necchi A, Mariani L, Zaffaroni N, **Giannatempo P**, Salvioni R.I. New directions for biologic targets in urothelial carcinoma – letter. *Mol Cancer Ther* 2012;11:2306
4. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, **Giannatempo P**, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. *Lancet Oncol* 2012;Aug13(8):810-16
5. **Giannatempo P**, Paolini B, Miceli R, Raggi D, Nicolai N, Farè E, Catanzaro M, BIASONI D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A. Persistence of CD30 expression by embryonal carcinoma in the treatment time-course: prognostic significance of a worthwhile target for a personalized treatment. *J Urol* 2013 Apr 25
6. Necchi A, Nicolai N, Mariani L, Raggi D, Farè E, **Giannatempo P**, Catanzaro M, BIASONI D, Torelli T, Stagni S, Milani A, Piva L, Pizzocaro G, Gianni AM, Salvioni R. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ-cell tumors. Long-term efficacy and safety outcomes. *Ann Oncol* 2013
7. Necchi A, Nicolai N, Mariani L, Lo Vullo S, **Giannatempo P**. Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. *Clin Genitourin Cancer*. 2013 Oct 23.
8. Lughezzani G, Catanzaro M, Torelli T, Piva L, BIASONI D, Stagni S, Necchi A, **Giannatempo P**. The Relationship Between Lymph Node Ratio and Cancer-Specific Survival in a Contemporary Series of Patients with Penile Cancer and Lymph Node Metastases. *BJU Int*. 2013 Oct 15.

9. Necchi A, Pennati M, Zaffaroni N, Landoni E, **Giannatempo P**. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. *British Journal of Cancer* (2013), 1–8.
10. Necchi A, Mariani L, **Giannatempo P**, et al. Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. *Clin Genitourin Cancer* 2013 Nov 21.
11. Necchi A, **Giannatempo P** et al. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGF β) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. *Invest New Drugs*. 2014 Feb 26.
12. Necchi A, Miceli R, Pedrazzoli P, **Giannatempo P** et al. Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. *Clin Genitourin Cancer* 2013 Nov 13.
13. Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, Necchi A, **Giannatempo P** et al. The Relationship Between Lymph Node Ratio and Cancer-Specific Survival in a Contemporary Series of Patients with Penile Cancer and Lymph Node Metastases. *BJU Int*. 2013 Oct 15.
14. Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, Crestani A, Guttilla A, Raggi D, Giannatempo P et al. The Relationship between Characteristics of Inguinal Lymph Nodes and Pelvic Lymph Node Involvement in Penile Squamous Cell Carcinoma: A Single Institution Experience. *J Urol*. 2014 Apr;191(4):977-82.
15. **Giannatempo P**, Greco P, Mariani L, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. *Ann Oncol* 2014, Sep 11
16. Necchi A, **Giannatempo P**, Paolini B, et al. Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. *Clin Genitourin Cancer* 2014, Aug 8
17. Raggi D, **Giannatempo P**, Miceli R, et al. Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMACO) for male patients with HCG-expressing, chemoresistant germ cell tumors. *Am J Clin Oncol* 2014, Aug 7
18. Necchi A, **Giannatempo P**, Lo Vullo S, et al. A prognostic model including pre- and post-surgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center. *Clin Genitourin Cancer* 2014, Jun 24
19. Necchi A, **Giannatempo P**, Lo Vullo S, et al. Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design. *Clin Genitourin Cancer* 2014, Jun 11
20. Giannatempo P, Alessi A, Miceli R, et al. Interim fluorine-18 Fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. *Clin Genitourin Cancer* 2014, Mar 28
21. Necchi A, Pond GR, **Giannatempo P**, et al. Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. *Clin Genitourin Cancer* 2014
22. Necchi A, Raggi D, **Giannatempo P** et al. Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. *Clin Genitourin Cancer*. 2015;13:80-6.
23. Necchi A, Mariani L, Di Nicola M, Raggi D, Lo Vullo S, Nicolai N, **Giannatempo P** et al. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment for patients with poor prognosis germ cell tumors: mature results of an Italian randomized phase II study. *Ann Oncol*. 2015;26:167-72.
24. Nicolai N, Necchi A, Raggi D, Biasoni D, Catanzaro M, Piva L, Stagni S, Maffezzini M, Torelli T, Faré E, **Giannatempo P**, Pizzocaro G, Colecchia M, Salvioni R. *Urology* 2015;85:402-6.
25. Necchi A, Faré E, Lo Vullo S, **Giannatempo P**, et al. Clinical outcomes of metastatic poor prognosis germ cell tumors: current perspective from a referral center. *Clin Genitourin cancer* 2015
26. Raggi D, Mariani L, **Giannatempo P**, Lo Vullo S, Giardiello D, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Calareso G, Magni M, Di Nicola M, Verzoni E, Grassi P, Procopio G, De Braud F, Pizzocaro G, Salvioni R, Necchi A. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. *Urol Oncol*. 2015 Jul;33(7):332.e19-24.
27. Zanardi E, Verzoni E, Grassi P, Necchi A, **Giannatempo P**, Raggi D, De Braud F, Procopio G. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. *Ther Adv Urol*. 2015 Jun;7(3):152-61.
28. Necchi A, Nicolai N, **Giannatempo P**, Raggi D, Miceli R, Mariani L, Salvioni R. The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors? *Clin Genitourin Cancer*. 2015 Aug 6.

29. Nicolai N, Sangalli LM, Necchi A, **Giannatempo P**, Paganoni AM, Colecchia M, Piva L, Catanzaro MA, Biasoni D, Stagni S, Torelli T, Raggi D, Faré E, Pizzocaro G, Salvioni R. A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. *Clin Genitourin Cancer*. 2015 Aug 6. pii: S1558-7673(15)00182-2.
30. Necchi A, **Giannatempo P**, Lo Vullo S, Raggi D, Nicolai N, Colecchia M, Perrone F, Mariani L, Salvioni R. Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. *Clin Genitourin Cancer*. 2015 Aug 11. pii: S1558-7673(15)00197-4
31. Necchi A, Nicolai N, Alessi A, Miceli R, **Giannatempo P**, Raggi D, Tana S, Serafini G, Padovano B, Mariani L, Crippa F, Salvioni R. Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. *Clin Genitourin Cancer*. 2015 Sep 5.
32. **Giannatempo P**, Pond GR, Sonpavde G, Albany C, Lortol Y, Sweeney CJ, Salvioni R, Colecchia M, Nicolai N, Raggi D, Rice KR, Flack CK, El Mouallem NR, Feldman H, Fizazi K, Einhorn LH, Foster RS, Necchi A, Cary C. Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation: an International collaboration. *J Urol*. 2015 Dec 31
33. Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, **Giannatempo P**, Necchi A, Flechon A, Boyle H, Chung P, Huddart RA, Bokemeyer C, Tryakin A, Sava T, Winquist EW, De Giorgi U, Aparicio J, Sweeney CJ, Cohn Cedermarck G, Beyer J, Powles T. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group. *J Clin Oncol*. 2016 Feb 1;34(4):345-51.
34. Raggi D, Miceli R, Sonpavde G, **Giannatempo P**, Mariani L, Galsky MD, Bellmunt J, Necchi A. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. *Ann Oncol*. 2016 Jan;27(1):49-61.
35. **Giannatempo P**, Pond GR, Sonpavde G, Raggi D, Naik G, Galsky MD, Bellmunt J, Necchi A. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. *Eur Urol*. 2016 Apr;69(4):624-633.
36. Necchi A, Lo Vullo S, Mariani L, Raggi D, **Giannatempo P**, Calareso G, Togliardi E, Crippa F, Di Genova N, Perrone F, Colecchia M, Paolini B, Pelosi G, Nicolai N, Procopio G, Salvioni R, De Braud FG. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. *Invest New Drugs*. 2016 Apr;34(2):236-42
37. Necchi A, Lo Vullo S, Nicolai N, Raggi D, **Giannatempo P**, Colecchia M, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, Mariani L, Salvioni R. Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. *Clin Genitourin Cancer*. 2016 Dec;14(6):518-523
38. Necchi A, Anichini A, Raggi D, **Giannatempo P**, Magazzù D, Nicolai N, Colecchia M, Paolini B, Coradeschi E, Tassi E, Grazia G, Mortarini R, Calareso G, De Fato R, Togliardi E, Crippa F, Salvioni R, Valagussa P, Gianni AM. Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. *Clin Genitourin Cancer*. 2016 Aug;14(4):261-26
39. Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, **Giannatempo P**, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. *Clin Genitourin Cancer*. 2016 Dec;14(6):494-498
40. Nicolai N, Cattaneo F, Biasoni D, Catanzaro M, Torelli T, Zazzara M, Necchi A, **Giannatempo P**, Raggi D, Piva L, Colecchia M, Salvioni R, Stagni S. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. *J Endourol*. 2016 Oct;30(10):1112-1119.
41. Necchi A, Pond GR, Nicolai N, **Giannatempo P**, Raggi D, Adra N, Hanna NH, Salvioni R, Einhorn LH, Albany C. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. *Clin Genitourin Cancer*. 2016 Aug 8
42. Necchi A, Miceli R, Oualla K, Sonpavde G, **Giannatempo P**, Raggi D, Nicolai N, Boffi R, Busia A, Mariani L, Salvioni R. Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. *Clin Genitourin Cancer*. 2016 Sep 8
43. Fina E, Necchi A, **Giannatempo P**, Colecchia M, Raggi D, Daidone MG, Cappelletti V. Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma. *Bladder Cancer*. 2016 Oct 2

44. Necchi A, Pond GR, Raggi D, **Giannatempo P**, Vogelzang NJ, Grivas P, Galsky MD, Bellmunt J, Sonpavde G. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. *Clin Genitourin Cancer*. 2017 Feb;15(1):23-30
45. Necchi A, Lo Vullo S, Bregni M, Rosti G, Mariani L, Raggi D, **Giannatempo P**, Secondino S, Schumacher K, Massard C, Kanfer E, Oechsle K, Laszlo D, Michieli M, Ifrah N, Mercier M, Crysandt M, Wuchter P, Nagler A, Wahlin A, Martino M, Badoglio M, Pedrazzoli P, Lanza F. Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. *Clin Genitourin Cancer*. 2017 Feb;15(1):163-167.
46. Necchi A, Pintarelli G, Raggi D, **Giannatempo P**, Colombo F. Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib. *Invest New Drugs*. 2017 Feb 3
47. Necchi A, Raggi D, Volpi CC, **Giannatempo P** et al. Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical Research. *Eur Urol Focus*. 2017 Aug 27. pii: S2405-4569(17)30194-3
48. Necchi A, Lo Vullo S, Rosti G, Badoglio M, **Giannatempo P** et al. Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database. *Bone Marrow Transplant*. 2017 Aug;52(8):1218-1220. doi: 10.1038/bmt.2017.106. Epub 2017 Jun 5.
49. Necchi A, Raggi D, **Giannatempo P** et al. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. *Clin Genitourin Cancer*. 2017 Oct;15(5):509-512.e9. doi: 10.1016/j.clgc.2017.04.008. Epub 2017 Apr 13.
50. Necchi A, Lo Vullo S, **Giannatempo P** et al. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. *Ann Oncol*. 2017 Jun 1;28(6):1346-1351
51. Necchi A, Raggi D, **Giannatempo P**, Sonpavde G, Galsky MD, Bellmunt J, Mariani L, Miceli R. et al. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. *Clin Genitourin Cancer*. 2017 Oct;15(5):509-512.e9
52. Necchi A, Lo Vullo S, Secondino S, Rosti G, Badoglio M, **Giannatempo P**, Raggi et al. European Society for Blood and Marrow Transplantation, Cellular Therapy & Immunobiology Working Party – Solid Tumor sub-committee. Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant*. 2018 Jan 24
53. Necchi A, Lo Vullo S, **Giannatempo P** et al. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. *Clin Genitourin Cancer*. 2017 Oct 7. pii: S1558-7673(17)30306-3
54. Necchi A, Rink M, Giannatempo P, Raggi D, Xylinas E. Immunotherapy for metastatic urothelial carcinoma: status quo and the future. *Curr Opin Urol*. 2018 Jan;28
55. Necchi A, Eigl BJ, Yang ES, Bae S, Chandrashekar D, Chen D, Naik G, Mehta A, **Giannatempo P**, Colecchia M, Gordetsky J, Wei S, Cooper T, Varambally S, Sonpavde G. Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. *Eur Urol Focus*. 2018 Sep;4(5):733-736
56. Necchi A, Lo Vullo S, Raggi D, Perrone F, Giannatempo P, Calareso G, Togliardi E, Nicolai N, Piva L, BIASONI D, Catanzaro M, Torelli T, Stagni S, Colecchia M, Busico A, Pennati M, Zaffaroni N, Mariani L, Salvioni R. Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. *Urol Oncol*. 2018 Jan;36(1):8.
57. Necchi A, Lo Vullo S, Perrone F, Raggi D, **Giannatempo P**, Calareso G, Nicolai N, Piva L, BIASONI D, Catanzaro M, Torelli T, Stagni S, Togliardi E, Colecchia M, Busico A, Gloghini A, Testi A, Mariani L, Salvioni R. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. *BJU Int*. 2018 Mar;121(3):348-356.
58. Nicolai N, Tarabelloni N, Gasperoni F, Catanzaro M, Stagni S, Torelli T, Tesone A, Bettin L, Necchi A, **Giannatempo P**, Raggi D, Colecchia M, Piva L, Salvioni R, Paganoni AM, Pizzocaro G, BIASONI D. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. *J Urol*. 2018 Mar;199(3):741-747

59. Necchi A, Raggi D, **Giannatempo P**, Alessi A, Serafini G, Colecchia M, Ali SM, Chung JH. Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. *Eur J Cancer*. 2018 Jun;96:128-130.
60. Raggi D, Necchi A, **Giannatempo P**. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. *Future Oncol*. 2018 Nov;14(26):2683-2690.
61. Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, **Giannatempo P**, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. *J Urol*. 2018 Dec;200(6):1207-1214.
62. Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, **Giannatempo P**, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. *Ann Oncol*. 2018 Aug 1;29(8):1658-1686.
63. Necchi A, **Giannatempo P**, Raggi D, Mariani L, Colecchia M, Farè E, Monopoli F, Calareso G, Ali SM, Ross JS, Chung JH, Salvioni R. An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. *Eur Urol*. 2019 Jan;75(1):201-203.
64. Oing C, **Giannatempo P**, Honecker F, Oechsle K, Bokemeyer C, Beyer J. Palliative treatment of germ cell cancer. *Cancer Treat Rev*. 2018 Dec;71:102-107.
65. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, **Giannatempo P**, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *J Clin Oncol*. 2018 Oct 20;JCO1801148.
66. Banna GL, Nicolai N, Palmieri G, Ottaviano M, Balzarini L, Barone D, Basso U, Bavila A, Bertoni F, Calliada F, Cai T, Carrafiello G, Condello C, Da Pozzo L, Di Nardo D, Fornarini G, Prayer Galetti T, Garolla A, **Giannatempo P** et al. Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. *Crit Rev Oncol Hematol*. 2019 May;137:154-164.
67. Signorelli D, **Giannatempo P** et al. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. *Biomed Res Int*. 2019 Apr 24;2019:9056417.
68. Marandino L, Raggi D, **Giannatempo P** et al. Erdafitinib for the treatment of urothelial cancer. *Expert Rev Anticancer Ther*. 2019 Oct;19(10):835-846.
69. Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordo T, Maroto P, Ravaud A, Durán I, Szabados B, Castellano D, **Giannatempo P** et al. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. *Eur Urol*. 2019 Nov 5. pii: S0302-2838(19)30770-5
70. Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, **Giannatempo P** et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. *Eur Urol*. 2019 Nov 8. pii: S0302-2838(19)30825-5.
71. Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, Colecchia M, Marandino L, Bianchi M, Gallina A, Colombo R, Fossati N, Gandaglia G, Capitanio U, Dehò F, **Giannatempo P** et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. *Eur Urol*. 2019 Dec 24. pii: S0302-2838(19)30960-1.
72. Necchi A, Raggi D, **Giannatempo P**, Marandino L, Farè E, Gallina A, Colecchia M, Lucianò R, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Dittamore R, Liu Y, Davicioni E, Ross JS, de Jong JJ, Briganti A, Montorsi F, Gibb EA. Can Patients With Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment From the Updated Results of the PURE-01 Study. *Eur Urol Oncol* 2020 May 14;S2588-9311(20)30053-5
73. Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, Colecchia M, Marandino L, Bianchi M, Gallina A, Colombo R, Fossati N, Gandaglia G, Capitanio U, Dehò F, **Giannatempo P**, Lucianò R, Salonia A, Madison R, Ali SM, Chung JH, Ross JS, Briganti A, Montorsi F, De Cobelli F, Messina A. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings

from the PURE-01 Study. *Eur Urol.* 2020 May;77(5):636-643. doi: 10.1016/j.eururo.2019.12.016. Epub 2019 Dec 25. PMID: 31882281

74. Necchi A, Raggi D, Gallina A, Ross JS, Farè E, **Giannatempo P**, Marandino L, Colecchia M, Lucianò R, Bianchi M, Colombo R, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Capitanio U, Montorsi F, de Jong JJ, Dittamore R, Liu Y, Davicioni E, Boormans JL, Briganti A, Black PC, Gibb EA. 4. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. *Eur Urol.* 2020 Jun;77(6):701-710. D10.1016/j.eururo.2020.02.028. Epub 2020 Mar 9. PMID: 32165065

75. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, **Giannatempo P**, Necchi A, Aurilio G, Casadei C, Tran B, Dieckmann KP, Brito M, Ruf C, Oing C, Bokemeyer C. Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). *Eur J Cancer.* 2020 Jun;132:127-135. doi: 10.1016/j.ejca.2020.03.022. Epub 2020 Apr 29. PMID: 3236138

76. Necchi A, Raggi D, **Giannatempo P**, Marandino L, Farè E, Gallina A, Colecchia M, Lucianò R, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Dittamore R, Liu Y, Davicioni E, Ross JS, de Jong JJ, Briganti A, Montorsi F, Gibb EA. Can Patients With Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment From the Updated Results of the PURE-01 Study. *Eur Urol Oncol* 2020 May 14;S2588-9311(20)30053-5

77. Bandini M, Ross JS, Raggi D, Gallina A, Colecchia M, Lucianò R, **Giannatempo P**, Farè E, Pederzoli F, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Deho' F, Ali SM, Madison R, Chung JH, Salonia A, Briganti A, Montorsi F, Necchi A. Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer. *J Natl Cancer Inst.* 2020 Jun 9. PMID: 32516377

78. Bandini M, Calareso G, Raggi D, Marandino L, Colecchia M, Gallina A, **Giannatempo P**, Pederzoli F, Gandaglia G, Fossati N, Capitanio U, Colombo R, Salonia A, Briganti A, Montorsi F, De Cobelli F, Messina A, Necchi A. The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. *A. Eur Urol Oncol.* 2020 Jun 27;S2588-9311(20)30082-1. PMID: 32605888

79. Pederzoli F, Bandini M, Marandino L, Raggi D, **Giannatempo P**, Salonia A, Gallina A, Briganti A, Montorsi F, Necchi A. Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? *Eur Urol Oncol.* 2020 Aug 23;S2588-9311(20)30121-8. PMID: 32847746

80. Porta C, **Giannatempo P**, Rizzo M, Lucarelli G, Ditunno P, Battaglia M. An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. *Expert Opin Pharmacother.* 2020 Sep 1:1-6 PMID: 32870051

81. Bandini M, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres B, Hakenberg OW, Heidenreich A, Raggi D, **Giannatempo P**, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. *Eur Urol Oncol.* 2020 Sep 14;S2588-9311(20)30122-X. PMID: 32943378

82. Bandini M, Ross JS, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres BA, Hakenberg OW, Heidenreich A, Salvioni R, Catanzaro M, Raggi D, **Giannatempo P**, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. *Eur Urol Oncol.* 2020 Nov 13;S2588-9311(20)30176-0

83. Marandino L, Capozza A, Bandini M, Raggi D, Farè E, Pederzoli F, Gallina A, Capitanio U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, **Giannatempo P**, Serafini G, Padovano B, Salonia A, Briganti A, Montorsi F, Alessi A, Necchi A. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. *Urol Oncol.* 2020 Oct 15;S1078-1439(20)30472-5.

84. **Giannatempo P**, Raggi D, Marandino L, Bandini M, Farè E, Calareso G, Colecchia M, Gallina A, Ross JS, Alessi A, Briganti A, Montorsi F, Madison R, Necchi A. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study *Ann Oncol.* 2020 Dec;31(12):1764-1772

85. Bandini M, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres B, Hakenberg OW, Heidenreich A, Raggi D, **Giannatempo P**, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Contemporary Treatment Patterns and Outcomes for Patients with Penile

Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. *Eur Urol Oncol*. 2021 Feb;4(1):121-123.

86. Bandini M, Ross JS, Raggi D, Gallina A, Colecchia M, Lucianò R, **Giannatempo P**, Farè E, Pederzoli F, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Deho' F, Ali SM, Madison R, Chung JH, Salonia A, Briganti A, Montorsi F, Necchi A. Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. *J Natl Cancer Inst*. 2021 Jan 4

87. Bersanelli M, Buti S, **Giannatempo P**, Raggi D, Necchi A, Leonetti A, Banna GL, Petrelli F. Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2021 Mar.

88. Marandino L, Capozza A, Bandini M, Raggi D, Farè E, Pederzoli F, Gallina A, Capitanio U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, **Giannatempo P**, Serafini G, Padovano B, Salonia A, Briganti A, Montorsi F, Alessi A, Necchi A. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. *Urol Oncol*. 2021 Apr;39(4):235

89. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, Hermanns T, Aparicio J, Heinzlbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, **Giannatempo P**, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C. The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). *World J Urol*. 2021 Mar 8.

90. Rizzo M, **Giannatempo P**, Porta C. Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. *Biologics*. 2021 Nov 1;15:441-450. doi: 10.2147/BTT.S290311.

91. Nazzani S, Stagni S, Biasoni D, Catanzaro M, Macchi A, Tesone A, Torelli T, Darisi R, Lo Russo V, Colbacchini C, Lanocita R, Cascella T, Claps M, **Giannatempo P**, Zimatore M, Cattaneo L, Montanari E, Salvioni R, Nicolai N. Laparoscopic retroperitoneal lymph-node dissection in metastatic nonseminomatous germ-cell tumors. *Eur J Surg Oncol*. 2022 Aug 19:S078-7983(22)00620-5.

92. Bersanelli M, Mazzaschi G, **Giannatempo P**, Raggi D, Farè E, Maruzzo M, Basso U, De Giorgi U, Vignani F, Banna GL, Stellato M, Tambaro R, Naglieri E, Losanno T, Procopio G, Pignata S, Necchi A, Buti S. Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). *Immunotherapy*. 2022 Feb;14(2):107-114.

93. Procopio G, Sepe P, Claps M, Buti S, Colecchia M, **Giannatempo P**, Guadalupi V, Mariani L, Lalli L, Fucà G, de Braud F, Verzoni E. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). *JAMA Oncol*. 2022 Jun 1;8(6):910-913.

94. Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, de Giorgi U, Basso U, Maruzzo M, **Giannatempo P**, Ponzano M, Giunta EF, Catalano F, Murianni V, Damassi A, Cremante M, Gandini A, Puglisi S, Llaja Obispo MA, Signori A, Banna GL. *Minerva Urol Nephrol*. 2022 Dec 13.

95. A novel immunotherapy prognostic score for patients with pretreated advanced urinary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.

96. Bacon JW, **Giannatempo P**, Cataldo G, Fazli L, Saxena N, Ozgun G, Soleimani M, Chi K, Nichols C, Necchi A, Wyatt AW, Kollmannsberger CK, Nappi L. TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors. *Oncologist*. 2022 Nov 3;27(11):e912-e915.

97. Raggi D, **Giannatempo P**, Marandino L, Pierantoni F, Maruzzo M, Lipari H, Banna GL, De Giorgi U, Casadei C, Naglieri E, Buti S, Bersanelli M, Stellato M, Santini D, Vignani F, Roviello G, Vecchia A, Caffo O, Losanno T, Calabrò F, Mucciarini C, Pignata S, Necchi A, Maio MD; MEET-URO Group. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study. *Clin Genitourin Cancer*. 2022 Apr;20(2):155-164.

98. Terbuch A, Posch F, Bauernhofer T, Jost PJ, Partl R, Stranzl-Lawatsch H, Baciarello G, Fizazi K, **Giannatempo P**, Verzoni E, Sweeney C, Ravi P, Tran B, Basso U, White J, Vincenzi B, Oing C, Cutuli HJ, Dieckmann KP, Gamulin M, Chovanec M, Fankhauser CD, Heidenreich A, Mohamad O, Thibault C, Fischer S, Gillesen S; International Germ Cell Cancer Collaborative Group. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2022 Jul 15;113(4):825-832.

99. Vignani F, Tambaro R, De Giorgi U, **Giannatempo P**, Bimbatti D, Carella C, Stellato M, Atzori F, Aieta M, Masini C, Hamzaj A, Ermacora P, Vecchia A, Scandurra G, Gamba T, Ignazzi G, Pignata S, Di Napoli M, Lolli C, Procopio G, Pierantoni F,

- Zonno A, Santini D, Di Maio M; Meet-URO12 Investigators. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. *Eur Urol*. 2023 Jan;83(1):82-89.
100. **Giannatempo P**, Nicolai N. What is the best way to treat patients with stage IIA or IIB seminoma? *Lancet Oncol*. 2022 Nov;23(11):1349-1350.
101. Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, de Giorgi U, Basso U, Maruzzo M, **Giannatempo P** et al. A novel immunotherapy prognostic score for patients with pretreated advanced urinary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score. *Minerva Urol Nephrol*. 2023 Jun;75(3):308-318
102. Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, **Giannatempo P** et al. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. *Eur J Cancer*. 2023 Mar;182:144-154
103. Bogani G, Cinquini M, Signorelli D, Pizzutilo EG, Romanò R, Bersanelli M, Raggi D, Alfieri S, Buti S, Bertolini F, Bonomo P, Marandino L, Rizzo M, Monteforte M, Aiello M, Tralongo AC, Torri V, Di Donato V, **Giannatempo P**. A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitors in solid tumors: The OTHERS study. *Crit Rev Oncol Hematol*. 2023 Jul;187:104016.
104. Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, Küronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, **Giannatempo P** et al. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. *Cancer Immunol Immunother*. 2023 Sep;72(9):2961-2970.
105. Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, Sexton WJ, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, **Giannatempo P** et al. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. *J Clin Oncol*. 2023 Dec 1;41(34):5296-5305
106. Necchi A, Basile G, Gibb EA, Raggi D, Calareso G, de Padua TC, Patanè D, Crupi E, Mercinelli C, Cigliola A, Tateo V, **Giannatempo P**, Moschini M, Briganti A, Montorsi F, Messina A, Ross JS, Pavlick D, De Cobelli F, Brembilla G. Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. *BJU Int*. 2024 Feb;133(2):214-222.
107. Pederzoli F, Riba M, Venegoni C, Marandino L, Bandini M, Alchera E, Locatelli I, Raggi D, **Giannatempo P** et al. Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer. *Eur Urol*. 2024 May;85(5):417-421.
108. Contieri R, Martini A, Mertens LS, **Giannatempo P**, Hurle R, Witjes JA, Ribal MJ, van Rhijn BWG, Malavaud B The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma. *Eur Urol Focus*. 2024 Jan 9:S2405-4569(23)00292-4.
109. Nazzani S, Catanzaro M, Bruniera M, Torelli T, Macchi A, Stagni S, Tesone A, Silvani C, Ceccato T, Bernasconi V, Lanocita R, Cascella T, Claps M, **Giannatempo P**, Zimatore M, Cattaneo L, BIASONI D, Montanari E, Nicolai N. Surveillance or Dynamic Sentinel Lymph-Node Biopsy in Low-Risk Clinically N0 Penile Squamous Cell Carcinoma: Single-Institution Real World Data. *Clin Genitourin Cancer*. 2024 Apr;22(2):544-548.
110. Necchi A, Ramlau R, Falcón González A, Chaudhry A, Todenhöfer T, Tahbaz R, Fontana E, **Giannatempo P** et al. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. *JNCI Cancer Spectr*. 2024 Apr 30;8(3):pkae030
111. García Del Muro X, Páez López-Bravo D, Cuéllar-Rivas MA, Maroto P, **Giannatempo P** et al. Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study *Eur Urol Oncol*. 2024 May 14:S2588-9311(24)00114-7
112. Gambale E, Maruzzo M, Messina C, De Gennaro Aquino I, Vascotto IA, Rossi V, Bimbatti D, Cavašin N, Messina M, Mennitto A, Rebuzzi SE, Nasso C, Mercinelli C, Maiorano BA, Fanelli M, Sorarù M, Scolari F, Mela MM, Galli L, Salfi A, Rizzo M, Puglisi S, Orlando V, Fornarini G, Rametta A, **Giannatempo P** et al. Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25). *Clin Genitourin Cancer*. 2024 Apr 24;22(4):102099

113. Necchi A, Basile G, Gibb EA, Raggi D, Calareso G, de Padua TC, Patanè D, Crupi E, Mercinelli C, Cigliola A, Tateo V, **Giannatempo P et al.** Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. *BJU Int.* 2024 Feb;133(2):214-222.
114. Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Kúronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, **Giannatempo P et al.** Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. *Cancer Immunol Immunother.* 2024 Apr 18;73(6):106.
115. Pederzoli F, Riba M, Venegoni C, Marandino L, Bandini M, Alchera E, Locatelli I, Raggi D, **Giannatempo P et al.** *Eur Urol.* 2024 May;85(5):417-421
116. Contieri R, Martini A, Mertens LS, **Giannatempo P**, Hurle R, Witjes JA, Ribal MJ, van Rhijn BWG, Malavaud B. The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma *Eur Urol Focus.* 2024 Jul;10(4):662-665

h-index / Citations

	Total
Citations	4623
h-index	33

Conference Abstracts

Oral presentation - ASCO (American Society of Clinical Oncology) annual meeting 2020
 Giannatempo P. et al. Final results of PEANUT: Pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC). *J Clin Oncol* 38: 2020 (suppl; abstr 5017)

Poster presentation - ASCO (American Society of Clinical Oncology) annual meeting 2021
 Marandino L, Giannatempo P et al. Clinical safety and activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy (ARCADIA): Preliminary results from a nonrandomized, open-label, phase 2 trial. *J Clin Oncol* 39, 2021 (suppl 15; abstr e16529)

Poster presentation – GU ASCO (Genitourinary Cancer Symposium) 2021
 Giannatempo P. A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study). 10.1200/JCO.2021.39.6_suppl.401

Oral presentation - ASCO (American Society of Clinical Oncology) 2018
 Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, Giannatempo P et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive

Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study Journal of Clinical Oncology 36, no. 34 (December 01, 2018) 3353-3360.

Poster presentation – GU ASCO (Genitourinary Cancer Symposium) 2015

Darren R. Feldman , Anja Lorch , Andrew Kramar , Costantine Albany , Lawrence H. Einhorn , Patrizia Giannatempo Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group. Journal of Clinical Oncology 34, no. 4 (February 01, 2016) 345-351.

Oral presentation - ASCO GU (Genitourinary Cancer Symposium) 2015

Giannatempo P. Et al. Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration. J Clin Oncol 33, 2015 (suppl 7; abstr 375)

Poster presentation – ESMO (European Society of Medical Oncology) 2014

Giannatempo P et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Abstract ID: 6686

Discussant at mino oral Session GU-non prostate. ESMO (European Society of Medical Oncology) 2023

Presentation by Expert: Management of advanced urothelial carcinoma: Does chemotherapy hold or lose its position? ESMO (European Society of Medical Oncology) 2024

PRESENTATIONS AND INVITED LECTURES

Keynote Address, EAU Faculty: 19th Meeting of the EAU Section of Oncological Urology 'Joint session of the ESOU and European Urology Oncology: Must-read papers in onco-urology 2021' (23 January 2022)

Workshop,

2020-2021-2022: Oper GU Masterclass- virtual - Italy

2019-2020 Faculty for ESMO bladder and kidney cancer preceptorship

2022 - Faculty for ESMO Guidelines: Real World Cases Webinar – Bladder Cancer

Invited as Discussant

2023: ESMO Congress 2023: discussant Mino-oral GU non-prostate session

2024: ESMO Congress 2024: Challenge Your Expert (CYE) - Management of advanced urothelial carcinoma: Does chemotherapy hold or lose its position?

GRANTS AND AWARDS

Research fellow, Fondazione IRCCS Istituto Nazionale dei Tumori di Milan, Italy
From 2012 – 2020

Honorary Clinical Fellowship, Lung Unit (Prof. Mary O'Brien)

Name of University, Royal Marsden Hospital London Sutton (UK)

March 2011 to Sep 2011

Clinical and research activities in medical oncology. Actively involved in weekly multidisciplinary and Journal Club meetings. Participation in clinical trials with new "target therapies" drugs including phase I studies

Clinical Visitor Trainee, Royal Marsden Hospital London Sutton (UK)

Genito-Urinary Unit (Prof. Horwich)

March 2011 to Sep 2011

Clinical experience in genitourinary medical oncology

Title of Award

Conquer Cancer Foundation of ASCO Merit Award (2015 Genito-Urinary Cancers Symposium), Orlando (FL, USA). 26-28 February 2015

Winner of the "Young Researchers Award 2014" (INT Milan, Italy) 15 April 2014

Flims 15° Workshop. 22- 28 June 2013

Markers Cancer Tutorial, Bruxelles. 05-07 November 2013

Winner of the Wide Angle Award 2013: "Fondazione Federico Calabresi" 19-20 December 2013

Title and Value of Grant

March 2015: Winner of the Post-Doctoral fellowships and Grant 2016 Foundation Umberto Veronesi

Title: "Next generation sequencing of teratoma with malignant transformation (TMT) to uncover potentially meaningful insights into the biology of germ cell tumors"

PATENTS (IF ANY)

none

PROFESSIONAL TRAINING

Name of course: 2nd Masterclass on systemic Review in Cancer Care, guidelines and Research ESO (European School of Oncology)

10-14 June 2016

Belfast, UK

Name of course: EORTC- Clinical Trial Statistics for Non Statisticians (Brussels-BE)

05-07 Nov 2013

Aim: introduction to the statistical methods used for the design, conduct and analysis of cancer clinical trials.

Name of workshop: 15th joint ECCO-AACR-EORTC-ESMO Workshop Methods in Clinical Cancer Research (Waldhaus Flims, Swiss).

22- 28 June 2013

Aim: to develop future leading clinical investigators in conducting clinical trials in cancer.

Title: Randomized, double-blind, placebo-controlled Phase III Study of standard frontline chemotherapy plus zoledronic acid in advanced or metastatic patients with urothelial cancer

Name of workshop:

Markers in Cancer: A joint workshop by ASCO, EORTC and NCI

05-07 November 2013

PROFESSIONAL AFFILIATIONS

- Associazione Italiana di Oncologia Medica (AIOM) - Panel member of: Italian National Guidelines AIOM Urothelial Carcinoma 2021-2023; Panel member of: Italian National Guidelines AIOM Germ cell Tumor 2020-2023
- European Society for Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- Italian Germ cell cancer Group (IGG)
- European Organization for the Research and Treatment of Cancer (EORTC) – Genito-Urinary Cancer group
- American Association for Cancer Research (AACR)
- European association of Urology (EAU)

PROFESSIONAL SERVICE

Peer-Reviewed Articles for:

- Lancet Oncology
- ESMO open
- Genito Urinary Cancer
- Future Oncology

Editorial Board Member:

- TJ Tumori Journal (Impact Factor 1.707)

Committee Member:

- Associazione Italiana di Oncologia Medica (AIOM) - Panel member of: Italian National Guidelines AIOM Urothelial Carcinoma 2021-2023; Panel member of: Italian National Guidelines AIOM Germ cell Tumor 2020-2023
- Italian Germ cell cancer Group (IGG) – member of board committee

- G3 - The Global Germ Cell Cancer Cooperative Group – member of board committee

COMMUNITY SERVICE

none

LANGUAGES

Italian: Native Language

English: Advanced Reading, Writing, Speaker and Listener

COMPUTER SKILLS

- Professional use of Excel, Power point, Microsoft Word, Prisma

OTHER

- masters swimming competitions, runner, mother of 3 kids

Milan 04 /09/24

